Tsubota Laboratory Inc is a Japan-based company mainly engaged in the research and development of new treatments for myopia, dry eye, and presbyopia. The Company operates with a B2B business model. The model generates revenue from lump-sum payments under joint research and development agreements and licensing agreements with partner companies, milestone payments, and royalties under post-commercialization (post-launch) loyalty agreements and creates new value by investing the profits in the new research. The Company is also engaged in the research and development of products for adults that treat depression and dementia, improve sleep and increase concentration.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-14	224.00 ¥	+2.28%	7,600
26-06-12	219.00 ¥	+0.46%	7,200
26-06-11	218.00 ¥	-0.91%	72,300
26-06-10	220.00 ¥	-1.35%	63,100
26-06-09	223.00 ¥	+0.45%	34,700

Delayed Quote Japan Exchange

More quotes

Income Statement and Estimates

More financial data

Delayed Japan Exchange Other stock markets 22:25:41 2026-06-14 EDT			5-day change	1st Jan Change
224.00 ^JPY	+2.28%		+0.90%	-34.12%

05-31	Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe	CI
05-31	Tsubota Laboratory Incorporated signed a letter of intent to acquire MediProduce, Inc. from Eri Kubota for ¥150 million.	CI

Market Cap	7.58B 47.34M 40.89M 37.68M 35.27M 66.1M 4.5B 67.12M 445M 173M 2.19B 178M 174M	P/E Ratio 2024	-14.1x	P/E Ratio 2025	49.7x
Enterprise Value	6.14B 38.3M 33.08M 30.48M 28.53M 53.48M 3.64B 54.3M 360M 140M 1.77B 144M 141M	EV / Sales 2024	10.8x	EV / Sales 2025	6.38x
Free-Float	27.85%	Yield 2024 *	-	Yield 2025	-

05-31	Tsubota Laboratory Incorporated announced that it expects to receive ¥4.129362 million in funding from Cantor Fitzgerald Europe	CI
05-31	Tsubota Laboratory Incorporated signed a letter of intent to acquire MediProduce, Inc. from Eri Kubota for ¥150 million.	CI
05-15	Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027	CI
02-13	Tsubota Laboratory Incorporated Provides Non Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026	CI
02-13	Tsubota Laboratory Incorporated Reports Earnings Results for the Nine Months Ended December 31, 2025	CI
25-05-11	Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2026	CI
25-02-17	Tsubota Laboratory Incorporated Revises Earnings Guidance for the Fiscal Year Ending March 31, 2025	CI
24-11-20	Tsubota Laboratory Incorporated Provides Earnings Guidance for the Fiscal Year Ending March 31, 2025	CI
22-12-18	Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 19-DEC-2022.	CI
22-09-19	Certain Common Stock of Tsubota Laboratory Incorporated are subject to a Lock-Up Agreement Ending on 20-SEP-2022.	CI
22-06-23	Tsubota Laboratory Incorporated has completed an IPO in the amount of Ã‘1.8048 billion.	CI
22-05-20	Tsubota Laboratory Incorporated has filed an IPO.	CI

1 day	+2.28%
1 week	+0.90%
Current month	-12.16%
1 month	-17.95%
3 months	-44.00%
6 months	-36.72%
Current year	-34.12%

Tsubota Laboratory Incorporated Stock

Stocks

4890

JP3535700003

Biotechnology & Medical Research

Valuation: Tsubota Laboratory Incorporated

Chart: Tsubota Laboratory Incorporated

Latest news : Tsubota Laboratory Incorporated

Quotes and Performance

Course Extremes

Managers and Directors: Tsubota Laboratory Incorporated

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Manager	Title	Age	Since
Kazuo Tsubota PSD	President	71	2019-01-31
Keisuke Mitsuoka ADM	Chief Administrative Officer	-	-
Kenji Morishima CTO	Chief Tech/Sci/R&D Officer	65	2024-12-31

Director	Title	Age	Since
Kazuo Tsubota BRD	Director/Board Member	71	2019-01-31
Shinichi Koizumi BRD	Director/Board Member	70	2020-05-31
Eri Kubota BRD	Director/Board Member	55	2023-05-31

Date	Insider	Type	Main position	Quantity	% Market Cap.
24-11-14	Kazuo Tsubota	Others	Founder	63,000	0.2465%
24-11-14	Kazuo Tsubota	Others	Founder	420,000	1.6434%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TSUBOTA LABORATORY INCORPORATED	+2.28%	+0.90%	-44.69%	-67.35%	35.26M
LONZA GROUP AG	-0.35%	+0.97%	-13.80%	-13.83%	43.03B
REVOLUTION MEDICINES, INC.	+3.11%	+3.11%	+279.08%	+509.39%	32.71B
IQVIA HOLDINGS INC.	+0.22%	-1.08%	+15.66%	-14.70%	30.29B
BEONE MEDICINES AG	+1.62%	-2.08%	-1.91%	+27.08%	29.4B
CELLTRION, INC.	+4.09%	+0.93%	+12.97%	+20.66%	25.08B
ASCENDIS PHARMA A/S	+1.14%	+3.62%	-	-	13.54B
MEDPACE HOLDINGS, INC.	-1.63%	+2.88%	+56.69%	+114.08%	13.35B
EUROFINS SCIENTIFIC SE	-0.40%	-1.29%	+6.23%	+6.41%	12.97B
IONIS PHARMACEUTICALS, INC.	-0.74%	-1.62%	+105.89%	+79.51%	12.11B
Average	+0.93%	+0.83%	+46.24%	+73.47%	21.25B
Weighted average by Cap.	+1.05%	+1.48%	+57.28%	+98.02%

	2024	2025
Net sales	673M 4.2M 3.63M 3.34M 3.13M 5.87M 399M 5.96M 39.48M 15.39M 194M 15.77M 15.43M	1.36B 8.47M 7.32M 6.74M 6.31M 11.83M 805M 12.01M 79.61M 31.04M 392M 31.79M 31.12M
Net income	-641M -4M -3.46M -3.18M -2.98M -5.59M -380M -5.67M -37.61M -14.66M -185M -15.02M -14.7M	205M 1.28M 1.11M 1.02M 953K 1.79M 122M 1.81M 12.03M 4.69M 59.21M 4.8M 4.7M
Net Debt	-1.77B -11.03M -9.53M -8.78M -8.22M -15.4M -1.05B -15.64M -104M -40.42M -510M -41.4M -40.52M	-1.45B -9.04M -7.81M -7.19M -6.73M -12.62M -859M -12.82M -84.95M -33.12M -418M -33.92M -33.2M

1 week	210	227
1 month	210	276
Current year	210	478
1 year	210	478
3 years	210	738
5 years	210	1,447
10 years	210	1,447